Adaptimmune Therapeutics Stock (NASDAQ: ADAP)

Adaptimmune Therapeutics

ADAPTIMMUNE THERAPEUTICS-ADR

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

February's Jobs Report Could Tip An Already Nervous Market Into Correction Territory

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ADAP

BHIL

ELEV

OPTN

WINT

Dow Gains Over 100 Points; Accenture Shares Plunge After Q2 Results

movers image

Pre-Market Outlook

Movers

AILE

AIMD

ANTE

CMAX

ESPR

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

HUMA

LGMK

MMAT

NDRA

PSIG

SNOA

TNON

YMAB

Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket

Biotech

Health Care

General

GLPG

FDA approves Adaptimmune Therapeutics&#39; Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large joints. Tecelra, the first engineered cell therapy for solid tumors in the U.S., showed a 43% ORR and a median response duration of six months.

FDA Approves Adaptimmune Therapeutics&#39; Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics PLC

ADAPad

Adappter Token

AdaptHealth Corp

ADAPTIVE AD SYSTEMS INC by Adaptive Ad Systems, Inc.

Adaptive Ad Systems Inc

Adaptive Alpha Opportunities ETF

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies Corp

Adaptive Core ETF

Adaptive Hedged Multi-Asset Income ETF

Press Releases

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Adaptimmune Reports Q3 2024 Financial and Business Updates

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Adaptimmune Provides Q4 and Full Year 2024 Business Update

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

AFFX

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Agenus

Anixa Biosciences

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Climb Bio

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

CervoMed

CytomX Therapeutics

Elicio Therapeutics

Elutia

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

I-MAB

Inozyme Pharma

Seres Therapeutics

MediciNova

OncoCyte

Sutro Biopharma

TScan Therapeutics

Instil Bio

Tenaya Therapeutics

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

XBiotech

Zura Bio Limited - Class A Ordinary shares

Zura Bio

HC Wainwright & Co.

Guggenheim

Wells Fargo

Scotiabank

Mizuho

Adaptive Brdbnd

Comments

Adaptimmune Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell